Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 8,715,665

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,715,665
Title:Methods for treating cancer resistant to ErbB therapeutics
Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
Inventor(s): Janne; Pasi A. (Newton, MA), Engelman; Jeffrey (Chestnut Hill, MA), Cantley; Lewis C. (Cambridge, MA)
Assignee: The General Hospital Corporation (Boston, MA) Dana Farber Cancer Institute (Boston, MA) Beth Israel Deaconess Medical Center (Boston, MA)
Application Number:12/450,826
Patent Claims:see list of patent claims

Details for Patent 8,715,665

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2027-04-13
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2027-04-13
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Try it Free 2027-04-13
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Try it Free 2027-04-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.